Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Trigemil Neuralgia (Tic Douloureux) - Overview
Trigemil Neuralgia (Tic Douloureux) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Trigemil Neuralgia (Tic Douloureux) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Trigemil Neuralgia (Tic Douloureux) - Companies Involved in Therapeutics Development
Acasti Pharma Inc
Amgen Inc
Biogen Inc
Biohaven Pharmaceutical Holding Company Ltd
Coda Biotherapeutics Inc
Hoba Therapeutics ApS
Initiator Pharma AS
InMed Pharmaceuticals Inc
Noema Pharma AG
Noveome Biotherapeutics Inc
OliPass Corporation
Oxford Canbinoid Technologies Ltd
Praxis Precision Medicines Inc
USA Elixiria Biotech Inc
Trigemil Neuralgia (Tic Douloureux) - Drug Profiles
basimglurant - Drug Profile
Product Description
Mechanism Of Action
History of Events
DKI-561 - Drug Profile
Product Description
Mechanism Of Action
ELB-00824 - Drug Profile
Product Description
Mechanism Of Action
erenumab - Drug Profile
Product Description
Mechanism Of Action
History of Events
Gene Therapy for Trigemil Neuralgia - Drug Profile
Product Description
Mechanism Of Action
GTX-201 - Drug Profile
Product Description
Mechanism Of Action
History of Events
HB-086 - Drug Profile
Product Description
Mechanism Of Action
INM-405 - Drug Profile
Product Description
Mechanism Of Action
IPTN-2021 - Drug Profile
Product Description
Mechanism Of Action
OCT-130401 - Drug Profile
Product Description
Mechanism Of Action
OLP-1002 - Drug Profile
Product Description
Mechanism Of Action
PRAX-562 - Drug Profile
Product Description
Mechanism Of Action
rimegepant sulfate ODT - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecule to Block TRPV4 and TRPA1 for Pancreatitis and Trigemil Neuralgia - Drug Profile
Product Description
Mechanism Of Action
ST-266 - Drug Profile
Product Description
Mechanism Of Action
vixotrigine - Drug Profile
Product Description
Mechanism Of Action
History of Events
Trigemil Neuralgia (Tic Douloureux) - Dormant Projects
Trigemil Neuralgia (Tic Douloureux) - Product Development Milestones
Featured News & Press Releases
Feb 22, 2022: Noema Pharma announces first patient dosed in Phase 2b LibraTN study of mGluR5 inhibitor NOE-101 in trigemil neuralgia
Feb 14, 2022: Noema Pharma announces FDA Investigatiol New Drug Authorization for Phase 2b LibraTN study of mGluR5 inhibitor NOE-101 in trigemil neuralgia
Oct 11, 2021: Oxford Canbinoid Technologies targets chronic pain condition with latest formulation
Jul 03, 2019: Biohaven starts enrolment in rimegepant’s trigemil neuralgia trial
Sep 23, 2014: Convergence Pharmaceuticals’ Novel v1.7 Selective Sodium Channel Blocker CNV1014802 Demonstrates Proof of Concept in Second Neuropathic Pain Study in Lumbosacral Radiculopathy
Jun 16, 2014: Convergence Pharmaceuticals’ Novel Sodium Channel Blocker CNV1014802 Shows Excellent Efficacy and Safety in Ground-breaking Phase II Trigemil Neuralgia Study
Jul 30, 2013: Convergence Pharmaceuticals Receives Orphan-Drug Desigtion for v1.7 Blocking Pain Drug CNV1014802
Apr 23, 2013: Convergence Pharma Announces Successful Interim Data From Phase II Trigemil Neuralgia Study
Mar 27, 2013: Convergence Pharma Reports Positive Interim Data From Phase II Trigemil Neuralgia Study Of CNV-1014802
Mar 19, 2012: Convergence Initiates Phase II Study For CNV1014802 For Trigemil Neuralgia
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development for Trigeminal Neuralgia (Tic Douloureux), 2022
Number of Products under Development by Companies, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022

List of Tables

List of Tables
Number of Products under Development for Trigeminal Neuralgia (Tic Douloureux), 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Trigeminal Neuralgia (Tic Douloureux) - Pipeline by Acasti Pharma Inc, 2022
Trigeminal Neuralgia (Tic Douloureux) - Pipeline by Amgen Inc, 2022
Trigeminal Neuralgia (Tic Douloureux) - Pipeline by Biogen Inc, 2022
Trigeminal Neuralgia (Tic Douloureux) - Pipeline by Biohaven Pharmaceutical Holding Company Ltd, 2022
Trigeminal Neuralgia (Tic Douloureux) - Pipeline by Coda Biotherapeutics Inc, 2022
Trigeminal Neuralgia (Tic Douloureux) - Pipeline by Hoba Therapeutics ApS, 2022
Trigeminal Neuralgia (Tic Douloureux) - Pipeline by Initiator Pharma AS, 2022
Trigeminal Neuralgia (Tic Douloureux) - Pipeline by InMed Pharmaceuticals Inc, 2022
Trigeminal Neuralgia (Tic Douloureux) - Pipeline by Noema Pharma AG, 2022
Trigeminal Neuralgia (Tic Douloureux) - Pipeline by Noveome Biotherapeutics Inc, 2022
Trigeminal Neuralgia (Tic Douloureux) - Pipeline by OliPass Corporation, 2022
Trigeminal Neuralgia (Tic Douloureux) - Pipeline by Oxford Cannabinoid Technologies Ltd, 2022
Trigeminal Neuralgia (Tic Douloureux) - Pipeline by Praxis Precision Medicines Inc, 2022
Trigeminal Neuralgia (Tic Douloureux) - Pipeline by USA Elixiria Biotech Inc, 2022
Trigeminal Neuralgia (Tic Douloureux) - Dormant Projects, 2022